Some observations on prope tolerance

Current Opinion in Organ Transplantation

Volumn 16, Issue 4, 2011, Pages 353-358

  Calne, Roy ^a   Watson, Christopher J E ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

alemtuzumab; campath; organ transplantation; tolerance

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; LEUKOCYTE ANTIGEN; MERCAPTOPURINE; MYCOPHENOLIC ACID; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; AFRICAN AMERICAN; BONE MARROW TRANSPLANTATION; CHIMERA; CLINICAL PROTOCOL; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; LEUKEMIA; LIVER FIBROSIS; LIVER FUNCTION; LIVER GRAFT; LOW DRUG DOSE; LUNG TRANSPLANTATION; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; MONOTHERAPY; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS ISLET TRANSPLANTATION; PATIENT COMPLIANCE; REGULATORY T LYMPHOCYTE; REVIEW; TISSUE TYPING; TRANSPLANTATION TOLERANCE; X IRRADIATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 80051822633     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328348b44c     Document Type: Review

References (58)

1. Anderson D, Billingham R, Lampkin G, Medawar P. The use of skin grafting to distinguish between monozygotic and dizygotic twins in cattle. Heredity 1951; 5:379-397.
2. Billingham R, Lampkin G, Medawar P, Williams H. Tolerance to homografts, twin diagnosis, and the freemartin condition in cattle. Heredity 1952; 6:201-212.
3. Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945; 102:400-401.
4. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172:603-606.
5. Merrill JP, Murray JE, Harrison JH, Guild WR. Successful homotransplantation of the human kidney between identical twins. JAMA 1956; 160:277-282.
6. Murray JE, Merrill JP, Harrison JH. Kidney transplantation between seven pairs of identical twins. Ann Surg 1958; 148:343-359.
7. MathéG, Thomas EG, Ferrebee JW. The restoration of marrow function after lethal irradiation in man: A review. Transpl Bull 1959; 6:407-409.
8. Billingham RE, Brent L. Quantitative studies on tissue transplantation immunity. IV. Induction of tolerance in newborn mice and studies on the phenomenon of runt disease. Phil Trans R Soc Lond B 1959; 242:439-477.
9. MathéG. Application of hematopoietic cell grafts to the treatment of leukemias and allied diseases: A critical review. Blood 1960; 16:1073-1088.
10. Merrill JP, Murray JE, Harrison JH, et al. Successful homotransplantation of the kidney between nonidentical twins. N Engl J Med 1960; 262:1251-1260.
11. Hamburger J, Vaysse J, Crosnier J, et al. Transplantation of a kidney between nonmonozygotic twins after irradiation of the receiver. Good function at the fourth month. Presse Med 1959; 67:1771-1775.
12. Calne RY. Inhibition of the rejection of renal homografts in dogs by purine analogues. Transpl Bull 1961; 28:65-81.
13. Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969; 223:472-476.
14. Reyes J, Zeevi A, Ramos H, et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc 1993; 25:3315-3319. (Pubitemid 24007333)
15. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J Hepatol 2009; 50:1247-1257.
16. Ohe H, Li Y, Nafady-Hego H, et al. Minimal but essential doses of immunosuppression: A more realistic approach to improve long-term outcomes for pediatric living-donor liver transplantation. Transplantation 2011; 91:808-810. This study shows the importance of a very low-dose maintenance immunosuppression in preventing a slow fibrosis in transplanted livers and is a cautionary argument in favour of this policy.
17. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323-327. (Pubitemid 18091075)
18. Waldmann H, Polliak A, Hale G, et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat antihuman lymphocyte antibody (CAMPATH-1). Lancet 1984; 2:483-486. (Pubitemid 14069763)
19. Hale G, Waldmann H. CAMPATH-1 monoclonal antibodies in bone marrow transplantation. J Hematother 1994; 3:15-31. (Pubitemid 24298195)
20. Clatworthy MR, Friend PJ, Calne RY, et al. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: Long-term follow-up. Transplantation 2009; 87:1092-1095.
21. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351:1701-1702. [erratum appears in Lancet 1998; 352:408]. (Pubitemid 28254534)
22. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76:120-129. (Pubitemid 36877125)
23. Knechtle SJ, Pirsch JD, H Fechner J Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3:722-730. (Pubitemid 36745245)
24. Barth RN, Janus CA, Lillesand CA, et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006; 19:885-892. (Pubitemid 44511112)
25. Flechner SM, Friend PJ, Brockmann J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005; 5:3009-3014. (Pubitemid 43923964)
26. Knechtle SJ, Pascual J, Bloom DD, et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: Clinical results and immune monitoring. Am J Transplant 2009; 9:1087-1098.
27. Mazariegos GV. Immunosuppression withdrawal after liver transplantation: What are the next steps? Transplantation 2011; 91:697-699.
28. Tryphonopoulos P, Madariaga JR, Kato T, et al. The impact of Campath 1H induction in adult liver allotransplantation. Transplant Proc 2005; 37:1203-1204. (Pubitemid 40590836)
29. Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: With particular reference to hepatitis C virus. Transplantation 2004; 78:966-971. (Pubitemid 39391856)
30. Tan HP, Donaldson J, Basu A, et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant 2009; 9:355-366.
31. Chaudhary A, Donaldson J, Shapiro R, et al. Alemtuzumab pretreatment and tacrolimus monotherapy for living donor kidney transplantation: Experience of first 200 cases with mean 6 year followup.AmJ Transplant 2011; 11 (Suppl 2): 146.
32. Shapiro R, Zeevi A, Basu A, et al. Alemtuzumab preconditioning with tacrolimus monotherapy: The impact of serial monitoring for donor-specific antibody. Transplantation 2008; 85:1125-1132. (Pubitemid 351590190)
33. Tan HP, Donaldson J, Ellis D, et al. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. Transplantation 2008; 86:1725-1731.
34. Vathsala A, Ona ET, Tan S-Y, et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80:765-774. (Pubitemid 41443758)
35. Margreiter R, Klempnauer J, Neuhaus P, et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial. Am J Transplant 2008; 8:1480-1485. (Pubitemid 351989498)
36. Watson CJE, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation: Efficacy and safety at five years. Am J Transplant 2005; 5:1347-1353. (Pubitemid 40839424)
37. Chan K, Galliford J, Goodall D, et al. 3 year results of a randomised controlled steroid sparing trial of campath and tacrolimus compared with daclizumab, tacrolimus and mycophenolate mofetil in renal transplantation. Am J Transplant 2011; 11 (Suppl 2):146.
38. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: Preliminary results. Transplantation 2004; 78:426-433. (Pubitemid 39095410)
39. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80:457-465. (Pubitemid 41209412)
40. Ortiz J, Palma-Vargas J, Wright F, et al. Campath induction for kidney transplantation: Report of 297 cases. Transplantation 2008; 85:1550-1556.
41. Ciancio G, Gaynor JJ, Roth D, et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. Transplant Proc 2010; 42:3503-3506.
42. Wright F, Kapturezak M, Bingaman A, et al. Alemtuzumab for kidney induction: 1000 cases over 8 years at a single center. Am J Transplant 2011; 11 (Suppl 2):146. This very large single-centre study of over 1000 cases gives a good overview of the whole idea of prope tolerance.
43. Africa J, Tucker M, Orquiza S, et al. Alemtuzumab induction with steroid free maintenance in African American kidney transplant recipients. Am J Transplant 2011; 11 (Suppl 2):209. An extremely important observation that alemtuzumab immunosuppression can improve results of transplants in African-Americans to the same level as other patients.
44. Baez YA, Giron FA. Alemtuzumab (campath-1 h) induction and prednisone: Free maintenance immunotherapy in kidney transplant Hispanic patients. Transplantation 2010; 90 (Suppl):65. An important study from a Latin American showing good results and importance of reduced costs.
45. Magliocca JF, Odorico JS, Pirsch JD, et al. A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. Am J Transplant 2008; 8:1702-1710.
46. Farney A, Sundberg A, Moore P, et al. A randomized trial of alemtuzumab vs. antithymocyte globulin induction in renal and pancreas transplantation. Clin Transplant 2008; 22:41-49. (Pubitemid 351150001)
47. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreaskidney transplantation comparison with rabbit antithymocyte globulin induction: Long-term results. Am J Transplant 2006; 6:331-339. (Pubitemid 43382168)
48. Sundberg AK, Roskopf JA, Hartmann EL, et al. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation. Transplant Proc 2005; 37:1294-1296. (Pubitemid 40590868)
49. Thai NL, Khan A, Tom K, et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One-and two-year outcomes. Transplantation 2006; 82:1621-1624. (Pubitemid 46035639)
50. Shapiro A, Toso C, Koh A, et al. Alemtuzumab induction and tac/mmf maintenance substantially improves long term insulin independence rates after clinical islet transplantation, and strongly suppresses both auto and alloreactivity. Transplantation 2010; 90 (Suppl):134. This study shows that alemtuzumab induction gives considerably better long-term results after islet transplantation.
51. McCurry KR, Iacono A, Zeevi A, et al. Early outcomes in human lung transplantation with thymoglobulin or campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005; 130:528-537. (Pubitemid 41074188)
52. van Loenhout KCJ, Groves SC, Galazka M, et al. Early outcomes using alemtuzumab induction in lung transplantation. Interact Cardiovasc Thorac Surg 2010; 10:190-194.
53. Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: One-year outcomes. Am J Transplant 2010; 10:382-388.
54. Bloom DD, Chang Z, Fechner JH, et al. CD4+CD25+FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008; 8:793-802. (Pubitemid 351347746)
55. Morales J, Bono MR, Fierro A, et al. Alemtuzumab induction in kidney transplantation: Clinical results and impact on T-regulatory cells. Transplant Proc 2008; 40:3223-3228.
56. Noris M, Casiraghi F, Todeschin iM, et al. Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18:1007-1018. (Pubitemid 46434518)
57. Pascual J, Bloom D, Torrealba J, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: Clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008; 8:1529-1536. (Pubitemid 351989487)
58. Trzonkowski P, Zilvetti M, Chapman S, et al. Homeostatic repopulation by CD28+CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008; 8:338-347.